Results 61 to 70 of about 294,417 (155)

New European records of Ditomyia macroptera Winnertz (Diptera: Ditomyiidae) with notes on its distribution

Biodiversity Data Journal, 2018
Olavi Kurina, Peter Chandler
doaj   +3 more sources

An Anoikis-Based Prognostic Signature Identifies MYC as a Key Regulator of Malignancy and Immunotherapy Resistance in Bladder Cancer

Frontiers in Bioscience-Landmark
Background: Resistance to anoikis is a critical mechanism that enables metastatic dissemination. Abrogation of this cellular safeguard is therefore a hallmark of aggressive cancer progression.
Zhen Tang, Jiao Peng, Xiaoyu Pan, Yuefeng Kong, Haisong Lin, Suchun Wei, Yi Zhan, Siping Zeng   +7 more
doaj   +1 more source

Vitamin D receptor expression in germinal centre type diffuse large B-cell lymphoma cells is associated with vitamin D insensitivity

Endocrine Oncology
Objective: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of non-Hodgkin lymphomas (NHLs) often sub-classified into major germinal centre (GC) and activated B-cell (ABC) cell-of-origin types.
Elizabeth J Soilleux, Amanda Anderson, Emma Roberts, Linden Lyne, Kah Keng Wong, Hayley Spearman, Stefano Casola, Alison H Banham, Duncan M Gascoyne   +8 more
doaj   +1 more source

c-Myc (MYC) [PDF]

Science-Business eXchange, 2014
openaire   +1 more source

Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology

Genes and Diseases
MYC is dysregulated in approximately 70% of human cancers, strongly suggesting its essential function in cancer. MYC regulates many biological processes, such as cell cycle, metabolism, cellular senescence, apoptosis, angiogenesis, and immune escape. MYC
Yingying Duan, Zhaoshuo Liu, Qilin Wang, Junyou Zhang, Jiaxin Liu, Ziyi Zhang, Chunyan Li   +6 more
doaj   +1 more source

c-Myc (MYC) [PDF]

Science-Business eXchange, 2011
openaire   +1 more source

Targeting both the enzymatic and non-enzymatic functions of DHODH as a therapeutic vulnerability in c-Myc-driven cancer

Cell Reports
Summary: c-Myc (Myc)-driven cancers exhibit aggressive phenotypes and therapeutic resistance. Here, integrating CRISPR-Cas9 screening, we identify dihydroorotate dehydrogenase (DHODH) as a promising target in Myc-driven cancer.
Qiang Zhang, Kaisa Cui, Yue Kong, Jing Yu, Zhanhao Luo, Xiaoya Yang, Liang Gong, Yanchun Xie, Jiuxiu Lin, Chen Liu, Zongjin Zhang, Yugeng Liu, Bingxin Liu, Dayi Liang, Wanyi Zeng, Zhen He, Ping Lan   +16 more
doaj   +1 more source

Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma

Nature Communications
The MYC oncogene is often dysregulated in human cancer, including hepatocellular carcinoma (HCC). MYC is considered undruggable to date. Here, we comprehensively identify genes essential for survival of MYC high but not MYC low cells by a CRISPR/Cas9 ...
Anja Deutzmann, Delaney K. Sullivan, Renumathy Dhanasekaran, Wei Li, Xinyu Chen, Ling Tong, Wadie D. Mahauad-Fernandez, John Bell, Adriane Mosley, Angela N. Koehler, Yulin Li, Dean W. Felsher   +11 more
doaj   +1 more source

Multitarget mechanism of MYC inhibition by the bacterial lon protease in disease

Scientific Reports
Identifying specific inhibitors of the MYC oncogene has been challenging, due to off target effects associated with MYC inhibition. This study investigated how the recombinant Escherichia coli Lon protease (rLon), which targets MYC in human cells ...
Ines Ambite, Murphy Lam Yim Wan, Hien Thi Tran, Atefeh Nazari, Arunima Chaudhuri, Christian Krintel, Inês Gomes, Samudra Sabari, Shahram Ahmadi, António N. B. M. Carneiro, Rita Ishac, Farhan Haq, Catharina Svanborg   +12 more
doaj   +1 more source

MYC matters [PDF]

Nature Reviews Cancer, 2010
openaire   +2 more sources